The discovery of antibodies is revolutionizing the treatment of chronic diseases such as cancer and autoimmune diseases. Beyond infection treatment, antibody discovery also helps to tackle complex treatments such as organ transplant, cesarean section, and chronic disease management. In recent years, there has been a surge in chronic diseases that validates the need for potential antibodies to effectively treat patients.
While monoclonal antibodies play an essential role in treatment of diseases, its low molecule binding specificity, posing challenges in the treatment of diseases such as solid tumors. The current situation encourages researchers to find next-generation antibodies that help to treat patients more efficiently. With the approval of next-generation therapies such as antibody-drug conjugates, genetic therapies, and Bispecific antibodies, researchers are pushing their edges by using modern technology for antibody discovery and looking forward to provide more antibodies based therapeutic solutions to treat diseases. Driven by these factors, the antibody discovery market is expected to grow in the future.
What are Antibodies?
Antibodies refer to the form of proteins that are produced in response to the infection by immune system. When infection causing pathogen enter into the body, these antibodies bind with antigen binding sites present on the cell surfaces of infectious agents and eliminate them either by blocking their pathway or directly killing them.
The production of improved therapeutic antibodies help to treat chronic diseases such as HIV, cancers, autoimmune disorders, and hereditary disorders. The revolutionizing technologies such as next-generation gene sequencing, hybridoma technology, phage display, genetic engineering, and recombinant technology allow researchers conduct in-depth research and discover potential antibodies for treatment.
Top Antibody Discovery Areas for Future Development
The evolution of antibodies resulted in the production of next-generation antibody therapeutics with advanced engineering processes to enhance characteristics like targeted cell-killing potency.
▪ Development of Antibody-Based Therapeutics Beyond Cancer Treatment
Monoclonal antibodies have been used for the treatment of autoimmune diseases, cancer, and infectious diseases. With improved antibody solutions such as Bispecific antibodies, ADC linker technology, antibody fragments, engineered antibodies, and nano-bodies, it is widely accepted for the treatment of other diseases such as neurodegenerative diseases, cardiovascular diseases, and metabolic diseases. In the future, the key antibody discovery platforms must focus on discovering smaller drug molecules that help to treat rare diseases.
▪ Multi-Specific Antibodies Discoveries
Multi-specific antibodies are specifically designed to target multiple antigen sites simultaneously. It provides higher efficacy and fewer side effects as compared to single-targeted antibodies. With modern technologies for production and designing, the development of multi-specific antibodies becomes easier. The emerging trend of designing multi-specific antibodies helps to grow the antibody discovery market in the future.
▪ Advanced Throughput Screening Technologies
Screening of the antibodies is the most challenging process during drug discovery. The advances in technology and integration of machine learning and artificial intelligence help to analyze enormous amounts of data in real time. These technologies may become more integrated within antibody discovery processes.
Current Antibody Discovery Market Landscape
Antibodies, specifically monoclonal antibodies, provide higher affinity for targeted cells, making them essential for the treatment of rare diseases. Though antibody drugs are available for treatment, the rising number of rare diseases and chronic infections fueled the demand for novel therapeutic antibodies to combat the microbial and genetic diseases persisting today. There is a growing demand for personalized medicine treatment, which relies on antibody discovery.
Many pharmaceutical leaders such as Alexis, Antibody Solutions, ChemPartner, GenScript, and Creative Biolabs are leveraging advance technology to provide antibodies based therapeutic drugs that are useful for the treatment of rare diseases. Examples of monoclonal antibodies based therapies that recently got approved include, ELREXFIO™ , Rystiggo® , TALVEY™, and COLUMVI®.
At the same time, continuous research is underway for the development of antibody discovery━expecting to come up with unique solutions. With the factors above, it is anticipated that the global antibody discovery market is expected to grow at a CAGR of 12% in the future, according to Roots Analysis.
Emerging Trends Increase the Antibody Discovery Market Growth
Increasing demand for improved antibody-based therapeutic drugs, advancement in biotechnology, ongoing expenditures on drug design and research, and outsourcing drug discovery trends have become the key drivers for the growth of the antibody discovery market.
▪ Next Generation Sequencing in Antibody Discovery
The next-generation sequencing techniques enable the analysis of large amounts of sequences simultaneously. The technology allows easy identification of potent antibodies and enhances the therapeutic efficacy of antibody-based therapies.
▪ Antibody-Drug Conjugates (ADCs) Adoption in Cancer Treatment
ADC represents the higher class of therapeutics that has the potential to treat chronic diseases such as cancer. When combined with cytotoxic drugs with antibodies, antibody-drug conjugates have the potential to selectively target cancerous cells without causing damage to nearby cells or tissues and, as a result, increase the therapeutic value.
▪ Therapeutic Antibodies For Personalized Medicines
Personalized treatment is a new way to treat patients with rare diseases. It uses patients’ genetic profiles to design the diagnosis, prevention, and treatment of the diseases. By determining the genetic profile, doctors can easily select antibody therapies and dosages for treatment. Notably, human genome sequence techniques here play a crucial role in therapeutic antibody discovery, resulting in the selection of more efficient antibodies.
▪ Development of Tri-Specific Antibody To Target Solid Tumors
Bispecific antibodies having two target sites have the potential to treat diseases such as hematological malignancies. However, the low efficacy of T cell engagers in solid tumors, and the immunosuppressive nature of the tumor reject the antibody therapeutic. To address this challenge, a more advanced Trispecific antibody has been designed. This re-engineered Trispecific T-cell has an ScFV fragment and two sdAbs (single-domain antibodies) that bind specifically to the multiple sites of targeted cells, resulting in targeting solid tumors.
The pharmaceutical companies remark on the beginning of vital antibody discoveries. The use of specialized technologies, research investment, and outsourcing trends helps to accelerate the production of antibodies to facilitate better treatment opportunities for patients. Thus, with emerging trends of antibody-drug discoveries, it is expected that the market will expand steadily in the coming years.
Who are the key Antibody Discovery Market Players?
Several key antibody discovery platforms are continuously working on advanced methodologies and workflows to provide more antibody solutions. Some of the key drug discovery players include;
▪ Alexis
▪ Antibody Solutions
▪ ChemPartner
▪ GenScript
▪ Creative Biolabs
▪ Genmab
▪ ImmunoPrecise
▪ Harbour BioMed
▪ Mabsilico
▪ Myrio Therapeutics
▪ Nona Biosciences
▪ Rockland Immunochemicals
▪ Synbio technologies
▪ WuXi Biologics.
Shifting Towards Bright Future of Antibody Discovery
Advances in technology help scientists to develop more antibodies for personalized treatment. Now, with the availability of genomics antibody discovery, companies have a better understanding of immunotherapies and ADCs. With more specific options available and ongoing research, the future of antibody discovery will continue to expand in the coming years.
About Roots Analysis
Roots Analysis is a global leader in the pharma/biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research/consulting services dedicated to serving our clients in the best possible way.
